Expertise in
1
conditions

Dagmar Hess

Kantonsspital St. Gallen, 
Sankt Gallen, SG, CH 
Expertise in
1
conditions
Kantonsspital St. Gallen, 
Sankt Gallen, SG, CH 
OverviewLocationsClinical Research

Overview

Dagmar Hess practices in Sankt Gallen, Switzerland. Ms. Hess is highly rated in 1 condition, according to our data. Her top areas of expertise are HER-2 Positive Breast Cancer, Agranulocytosis, Multiple Myeloma, and Breast Cancer.

Her clinical research consists of co-authoring 25 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Female

Locations

Kantonsspital St. Gallen, Sankt Gallen, SG, Switzerland
Other Locations
St Gallen, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors: A Multicenter Open-label Single-arm Phase I Trial
TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors: A Multicenter Open-label Single-arm Phase I Trial
Enrollment Status: Terminated
Publish Date: December 02, 2024
Intervention Type: Drug
Study Phase: Phase 1
Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. A Multicenter Phase Ib Trial With Two Expansion Cohorts
Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. A Multicenter Phase Ib Trial With Two Expansion Cohorts
Enrollment Status: Terminated
Publish Date: April 01, 2022
Intervention Type: Drug
Study Drugs: Copanlisib, Venetoclax
Study Phase: Phase 1
View 1 Less Clinical Trial

25 Total Publications

Open-label nonrandomized phase IB study to characterize the safety and recommended dose of tinostamustine in combination with nivolumab in patients with advanced melanoma (ENIgMA).
Open-label nonrandomized phase IB study to characterize the safety and recommended dose of tinostamustine in combination with nivolumab in patients with advanced melanoma (ENIgMA).
Journal: Melanoma research
Published: April 23, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Hess's expertise for a condition
ConditionClose
      View All 9 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile